NCT00843375 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
| NCT ID | NCT00843375 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan Rogel Cancer Center |
| Condition | Colonic Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2019-08-07 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2019-08-07 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.
Eligibility Criteria
Inclusion Criteria: * Willing to sign informed consent * Able to physically tolerate removal of up to 60 ml of blood * Adults at least 18 years old * Willing to collect 1-2 stool samples and prepare a Fecal Immunochemical Test (FIT) * Pregnant or nursing women who otherwise meet the eligibility criteria may participate * Subjects with one of the following: * Colorectal adenocarcinoma-not treated and in colon at time of stool collection (CRC bin) * Adenoma-pathologically confirmed adenoma present in colon at time of stool collection (Adenoma Bin) * Higher Risk Non-neoplastic Bin * Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy * Subjects with a personal history of CRC (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy * Any family history of CRC (1st degree relative) * Current positive screening stool test for blood, for DNA or for both within 12 months with no follow-up intervention. * Average Risk, Non-neoplastic Bin * No history or current finding of any colorectal neoplasia including CRC, adenomas, sessile serrated adenomas and no family history of CRC. * Subjects who had CRC that was successfully treated at least three years ago may be considered eligible for the adenoma bin if their polyps are adenomas and there is no evidence of CRC, or for the higher risk non-neoplastic bin as noted above. * Subjects whose screening colonoscopy shows any of these types of polyps may be included in the non-neoplastic or the higher risk non-neoplastic bin if they meet the other criteria noted above. * Hyperplastic polyps * Benign mucosal polyps * Polypoid granulation tissue * Prolapsed mucosal polyps * Inflammatory polyp * Transitional mucosal polyp * Lipoma * Gangleoneuroma * Neuroma * Hamartomatous polyp Exclusion Criteria: * Cancer patients who have had any surgery, radiation, or chemotherapy for their current colorectal cancer prior to collecting the baseline samples * History of or clinically active Inflammatory Bowel Disease * Known HNPCC or FAP * Inability to provide informed consent. * Other active malignancy within 3 years of enrollment except any of the following: * Squamous cell carcinoma of the skin * Basal cell carcinoma of the skin * Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only. (Excluded if had pelvic radiation) * Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery * Patients on active chemotherapy or radiation treatment for any purpose * Known HIV or chronic active viral hepatitis * Women who are pregnant * CT colonography (virtual colonoscopy) patients
Contact & Investigator
Dean E Brenner, M.D.
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT00843375 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colonic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00843375 currently recruiting?
Yes, NCT00843375 is actively recruiting participants. Contact the research team at CancerAnswerLine@med.umich.edu for enrollment information.
Where is the NCT00843375 trial being conducted?
This trial is being conducted at Los Angeles, United States, Urbana, United States, Boston, United States, Ann Arbor, United States and 9 additional locations.
Who is sponsoring the NCT00843375 clinical trial?
NCT00843375 is sponsored by University of Michigan Rogel Cancer Center. The principal investigator is Dean E Brenner, M.D. at University of Michigan. The trial plans to enroll 1,200 participants.